business
Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale?
Key takeaways
- The big issue on the market s mind is whether the company can survive the threat that AI s rise may pose to Doximity s operations.
- Our team just released a report on a little-known company, called an "Indispensable Monopoly," providing the critical technology Nvidia and Intel both need.
- Similarly, its Ask solution is a large language model tailored for doctors -- but may not offer enough differentiation from the leading AI companies today.
DOCS Shares of the leading digital platform for medical professionals, Doximity (NYSE: DOCS), dropped again earlier in May after the company reported fourth-quarter earnings, and the stock is now down a staggering 56% in 2026.
The big issue on the market s mind is whether the company can survive the threat that AI s rise may pose to Doximity s operations. For instance, the company s Scribe product, which transcribes and generates notes during doctor visits, is a somewhat "common" feature in today s AI-powered world.
Will AI create the world s first trillionaire? Our team just released a report on a little-known company, called an "Indispensable Monopoly," providing the critical technology Nvidia and Intel both need. Continue »
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop